{"organizations": [], "uuid": "552971948cc401d6d4e6673526eb6a02012b731f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/", "section_title": "Business &amp; Financial News, U.S &amp; International Breaking News | Reuters", "url": "https://www.reuters.com/article/us-cara-stocks/cara-therapeutics-signs-licensing-deal-with-vifor-fresenius-shares-surge-idUSKCN1IO1JA", "country": "US", "domain_rank": 408, "title": "Cara Therapeutics signs licensing deal with Vifor Fresenius, shares surge", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.137, "site_type": "news", "published": "2018-05-23T19:16:00.000+03:00", "replies_count": 0, "uuid": "552971948cc401d6d4e6673526eb6a02012b731f"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/us-cara-stocks/cara-therapeutics-signs-licensing-deal-with-vifor-fresenius-shares-surge-idUSKCN1IO1JA", "ord_in_thread": 0, "title": "Cara Therapeutics signs licensing deal with Vifor Fresenius, shares surge", "locations": [], "entities": {"persons": [{"name": "cara therapeutics", "sentiment": "negative"}, {"name": "korsuva", "sentiment": "none"}, {"name": "cara", "sentiment": "none"}, {"name": "mrinalini krothapalli", "sentiment": "none"}], "locations": [{"name": "south korea", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}, {"name": "united states", "sentiment": "none"}, {"name": "japan", "sentiment": "none"}], "organizations": [{"name": "vifor fresenius", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "cara therapeutics", "sentiment": "negative"}, {"name": "vifor fresenius medical care renal pharma ltd", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "(Reuters) - Shares of Cara Therapeutics surged more than 20 percent on Wednesday after it signed a licensing agreement with Vifor Fresenius Medical Care Renal Pharma Ltd that could give the U.S. drug developer up to $470 million in milestone payments.\nThe deal gives the kidney drug developer worldwide rights, except in the United States, Japan and South Korea, to sell Korsuva, Caraâ€™s injection for severe itching associated with chronic kidney disease in dialysis patients.\nCara will get an upfront payment of $50 million in cash and an equity investment of $20 million to acquire common stock at a price of about $17 per share, a premium of about 47 pct to its closing on Tuesday.\nCara began the first late-stage study for Korsuva injection in January and expects to start a similar study globally later in the year.\nReporting by Mrinalini Krothapalli\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-23T19:16:00.000+03:00", "crawled": "2018-05-23T14:54:44.017+03:00", "highlightTitle": ""}